Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions
| Autor: | Robert M. Issenman, Sally E. Tarbell, Irene Sarosiek, Safwan Jaradeh, Kathleen Adams, Ravi Sharaf, Thangam Venkatesan, B. U. K. Li, William L. Hasler, David J. Levinthal, Shahnaz Sultan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Marijuana Abuse
medicine.medical_specialty Vomiting Physiology Review Article Comorbidity The Guidelines on Management of Cyclic Vomiting Syndrome (CVS) in Adults Patient advocacy law.invention 03 medical and health sciences fluids and secretions 0302 clinical medicine Randomized controlled trial law medicine Humans migraine headaches Intensive care medicine Review Articles multicenter registry Cannabinoids Endocrine and Autonomic Systems Cyclic vomiting syndrome business.industry Mental Disorders Gastroenterology psychosocial dysfunction equipment and supplies medicine.disease Clinical trial Patient recruitment Cannabinoid hyperemesis syndrome Migraine Potential biomarkers 030211 gastroenterology & hepatology cyclic vomiting business 030217 neurology & neurosurgery |
| Zdroj: | Neurogastroenterology and Motility |
| ISSN: | 1365-2982 1350-1925 |
| Popis: | Cyclic vomiting syndrome (CVS) is characterized by severe episodic emesis in adults and children. Cannabinoid hyperemesis syndrome is an increasingly recognized CVS‐like illness that has been associated with chronic cannabis use. There are significant gaps in our understanding of the pathophysiology, clinical features, comorbidities, and effective management options of CVS. Recommendations for treating CVS are based on limited clinical data, as no placebo‐controlled, randomized trials have yet been conducted. Diseases associated with CVS, including migraine, mitochondrial disorders, autonomic dysfunction, and psychiatric comorbidities, provide clues about pathophysiologic mechanisms and suggest potential therapies. We review our current understanding of CVS and propose future research directions with the aim of developing effective therapy. Establishing a multicenter, standardized registry of CVS patients could drive research on multiple fronts including developing CVS‐specific outcome measures to broaden our understanding of clinical profiles, to serve as treatment end points in clinical trials, and to provide a platform for patient recruitment for randomized clinical trials. Such a robust database would also facilitate conduct of research that aims to determine the underlying pathophysiological mechanisms and genetic basis for CVS, as well as identifying potential biomarkers for the disorder. Soliciting government and industry support is crucial to establishing the necessary infrastructure and achieving these goals. Patient advocacy groups such as the Cyclic Vomiting Syndrome Association (CVSA), which partner with clinicians and researchers to disseminate new information, to promote ongoing interactions between patients, their families, clinicians, investigators, to support ongoing CVS research and education, must be an integral part of this endeavor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|